Research and Markets: Ophthalmology Drug Futures.

Research and Markets has announced the addition of the 'Ophthalmology Drug Futures' report to their offering. A complete and practical analysis of Ophthalmology Drugs packed with facts, figures and forecasts for launched and late-stage products. The $14 bn global ophthalmology sector faces both commercial challenge and clinical opportunity, and this report answers key questions. The market for drugs used to treat wet age-related macular degeneration (AMD) is estimated to be worth $3.3 bn. There are relatively few players and an increasing patient pool; continued growth is expected over the medium term. The current standard of care for wet AMD is Lucentis (ranibizumab), marketed by Roche …